Merck (MRK) Says FDA Granted Priority Review to its sBLA for GARDASIL9 in Women and Men Ages 27 to 45 for Prevention of Certain HPV-Related Cancers and Diseases
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
